Restricted accessResearch articleFirst published online 2023-3
Monitoring the safety of COVID-19 vaccination in pregnancy in the UK: A national study using the UK Obstetric Surveillance System (UKOSS),UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems
COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.
Methods
Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021.
Results
There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%).
Conclusion
Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.
KnightMBunchKCairnsACantwellRCoxPKenyonSKotnisRLucasNLucasSMarshallLNelson-PiercyCPageLRodgerAShakespeareJTuffnellDKurinczukJ. Saving Lives, Improving Mothers’ Care Rapid Report: Learning from SARS-CoV-2-related and associated maternal deaths in the UK March – May 2020, in Oxford University Rapid Report. 2020. Available from:www.npeu.ox.ac.uk/assets/downloads/mbrrace-uk/reports/MBRRACE-UK_Maternal_Report_2020_v10_FINAL.pdf.
2.
VousdenNBunchKMorrisESimpsonNGaleCO’BrienPQuigleyMBrocklehurstPKurinczukJJKnightM. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). PLoS ONE2021; 16(5): e0251123. PMID: 33951100.
3.
AlloteyJStallingsEBonetMYapMChatterjeeSKewTDebenhamLLlavallACDixitAZhouDBalajiRLeeSIQiuXYuanMCoomarDVan WelyMVan LeeuwenEKostovaEKunstHKhalilATiberiSBrizuelaVBroutetNKaraEKimCRThorsonAOladapoOTMofensonLZamoraJThangaratinamS. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. The BMJ2020; 370: m3320. PMID:32873575.
KnightMBunchKVousdenNMorrisESimpsonNGaleCObrienPQuigleyMBrocklehurstPKurinczukJJ. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National population based cohort study. The BMJ2020; 369: m2107. PMID: 32513659.
8.
KnightMMorrisRKFurnissJChappellLC. Include pregnant women in research - Particularly covid-19 research. The BMJ2020; 370: m3305. PMID: 32843352.
9.
BlakewayHPrasadSKalafatEHeathPTLadhaniSNLe DoareKMageeLAO'BrienPRezvaniADadelszenPVKhalilA. COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol, 2021. Online ahead of print, PMID: 34389291.
10.
Bookstein PeretzSRegevNNovickLNachsholMGofferEBen-DavidAAsrafKDoolmanRGal LevinERegev YochayGYinonY. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol2021; 58(3): 450–456. PMID: 34198360.
11.
GoldshteinINevoDSteinbergDMRotemRSGorfineMChodickGSegalY. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. JAMA2021; 326(8): 728–735. PMID: 34251417.
12.
Head ZaucheLWallaceBSmootsANOlsonCKOduyeboTKimSYPetersonEEJuJBeauregardJWilcoxAJRoseCEMeaney-DelmanDEllingtonSR. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. Res Sq, 2021. Online ahead of print (pre-print), PMID: 34401872.
13.
HillsonKClemensSCMadhiSAVoyseyMPollardAJMinassianAM and Oxford COVID Vaccine Trial Group. Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. The Lancet2021; 398(10312): 1683–1684. PMID: 34688353.
14.
KachikisAEnglundJASingletonMCovelliIDrakeALEckertLO. Short-term reactions among pregnant and lactating individuals in the first wave of the COVID-19 vaccine rollout. JAMA Netw Open2021; 4(8): e2121310. PMID: 34402893.
15.
KharbandaEOHaapalaJDeSilvaMVazquez-BenitezGVescoKKNalewayALLipkindHS. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA2021; 326(16): 1629–1631. PMID: 34495304.
16.
MagnusMCGjessingHKEideHNWilcoxAJFellDBHabergSE. Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage. N Engl J Med2021; 385(21): 2008–2010. PMID: 34670062.
RottenstreichMSelaHYRotemRKadishEWiener-WellYGrisaru-GranovskyS. Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. BJOG2021; 192(2): 248–255. PMID: 34554630.
20.
ShimabukuroTTKimSYMyersTRMoroPLOduyeboTPanagiotakopoulosLMarquezPLOlsonCKLiuRChangKTEllingtonSRBurkelVKSmootsANGreenCJLicataCZhangBCAlimchandaniMMba-JonasAMartinSWGeeJMMeaney-DelmanDM. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. The New England journal of medicine2021; 384(24): 2273–2282. PMID: 33882218.
21.
TheilerRNWickMMehtaRWeaverALVirkASwiftM. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am J Obstet Gynecol MFM2021; 3(6): 100467. PMID: 34425297.
22.
TrostleMELimayeMAAvtushkaMVLighterJLPenfieldCARomanAS. COVID-19 vaccination in pregnancy: early experience from a single institution. Am J Obstet Gynecol MFM2021; 3(6): 100464. PMID: 34411758.
KnightMKurinczukJJTuffnellDBrocklehurstP. The UK Obstetric Surveillance System for rare disorders of pregnancy. BJOG2005; 112(3): 263–265. PMID: 1571316.
27.
RichardsonJLMartinFDunstanHGreenallAStephensSYatesLMThomasSHL. Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study. Reproductive Toxicology2019; 84: 108–113. PMID: 30639403.
CustersJKimDLeyssenMGurwithMTomakaFRobertsonJHeijnenEConditRShukarevGHeerweghDvan HeesbeenRSchuitemakerHDouoguihMEvansESmithERChenRT. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine2021; 39(22): 3081–3101. PMID: 33676782.
35.
VousdenNRamakrishnanRBunchKMorrisESimpsonNGaleCO’BrienPQuigleyMBrocklehurstPKurinczukJJKnightM. Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. medRxiv2021. www.medrxiv.org/content/10.1101/2021.07.22.21261000v1.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
